OncoTargets and Therapy (Apr 2021)

Rapid Disease Progression in a Patient with Advanced NSCLC Harboring a Germline MET Exon 14 Skipping Mutation: A Case Report

  • Jiao Y,
  • Fang C,
  • Yang Y,
  • Shao L,
  • Huang Y,
  • Sun Q,
  • Dong Y

Journal volume & issue
Vol. Volume 14
pp. 2417 – 2421

Abstract

Read online

Yang Jiao,1,* Chen Fang,1,* Yuchen Yang,2 Lin Shao,2 Yi Huang,1 Qinying Sun,1 Yuchao Dong1 1Pulmonary and Critical Care Medicine, Changhai Hospital, The Naval Medical University, Guangzhou, People’s Republic of China; 2Burning Rock Biotech, Guangzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yuchao Dong; Qinying SunPulmonary and Critical Care Medicine, Changhai Hospital, The Naval Medical University, #168 Changhai Road, Yangpu District, Shanghai, 200433, People’s Republic of ChinaEmail [email protected]; [email protected]: MET exon 14 skipping variants have been identified as a novel type of oncogenic driver mutations in non-small-cell lung cancer (NSCLC), while the germline MET mutation, especially germline MET exon 14 skipping mutation rarely occurred in NSCLC. Herein, we present the first case of a 33-year-old NSCLC patient with a germline MET exon 14 skipping mutation, who also harbored a somatic EGFR exon 20 insertion. The patient was initially diagnosed with a stage IIB adenosquamous carcinoma. He underwent a thoracoscopic radical resection followed by four cycles of adjuvant chemotherapy but relapsed 2 months after completing the chemotherapy. Afatinib was then prescribed but disease progressed immediately. Subsequently, he received anlotinib but did not respond and died a month later with an overall survival of 9 months. Our case may provide an evidence for the pathogenicity of germline MET exon 14 skipping mutation in NSCLC and suggest it as an adverse prognostic factor.Keywords: MET exon 14 skipping mutation, rare germline mutation, next-generation sequencing, NGS, lung adenosquamous carcinoma, rapid disease progression

Keywords